HIM
BIO icon

Hillsdale Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Hillsdale Investment Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-16
Closed -$8K – 591
2020
Q3 		$8K Sell
16
-1
-6% -$507 ﹤0.01% 506
2020
Q2 		$8K Buy
+17
New +$7.5K ﹤0.01% 483

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Hillsdale Investment Management's BIO Position: Q4 2020 in Review

Hillsdale Investment Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2020, closing a stake of 16 shares — an estimated $8K sold.

Hillsdale Investment Management first reported a position in BIO in Q2 2020 and held it in 2 quarters. The position peaked at $8K in Q3 2020. 491 funds tracked by Wall St. Rank hold BIO as of Q4 2020.

  • Hillsdale Investment Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2020 after selling out during the quarter.
  • Hillsdale Investment Management sold 16 Bio-Rad Laboratories Class A shares in Q4 2020, an estimated $8K.
  • Hillsdale Investment Management first reported a position in Bio-Rad Laboratories Class A in Q2 2020 and held it in 2 quarters.
  • Hillsdale Investment Management's Bio-Rad Laboratories Class A position peaked at $8K in Q3 2020.
  • 491 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2020.

Based on Hillsdale Investment Management's 13F filing for Q4 2020, filed 9 Feb 2021.